Summary & Overview
HCPCS Level II M1020: Adolescent Depression 12-Month Non-Remission
HCPCS Level II code M1020 documents adolescent patients aged 12–17 with major depression or dysthymia who have not reached remission at the twelve-month follow-up. Remission is defined by a PHQ-9 or PHQ-9M score of less than 5 at twelve months (±60 days); this code applies when the twelve-month score is missing or is ≥5. The code captures longitudinal clinical status rather than a discrete procedure and is used to track treatment outcomes and quality measurement for pediatric behavioral health.
Key payers covered in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on the clinical criteria underlying the code, expected service settings (behavioral health and outpatient mental health), and the role of standardized depression measures in quality reporting. The publication summarizes benchmarking implications for national payer programs, clarifies the code’s measurement focus, and outlines what data elements are necessary to support accurate billing.
The material is intended for clinicians, billing professionals, quality officers, and policy analysts seeking a concise description of M1020, its clinical relevance, and how it fits into adolescent depression follow-up and quality measurement efforts. Data not available in the input: specific associated taxonomies, ICD-10 diagnoses, related codes, and service line detail.
Billing Code Overview
HCPCS Level II code M1020 indicates adolescent patients ages 12 to 17 with major depression or dysthymia who did not achieve remission at twelve months. Remission status is defined by a twelve month (+/-60 days) PHQ-9 or PHQ-9M score of less than 5; the code applies when either the PHQ-9 or PHQ-9M score was not assessed or is greater than or equal to 5 at the twelve-month interval.
Service type: Measurement and assessment of clinical remission status for adolescent depression at a twelve-month follow-up.
Typical site of service: Behavioral health or outpatient mental health settings where standardized depression screening instruments (PHQ-9 or PHQ-9M) are administered and documented for adolescents.
Clinical & Coding Specifications
Clinical Context
An adolescent patient, age 15, diagnosed with major depressive disorder (MDD) presents for a 12‑month follow‑up after initiation of psychotherapy and/or pharmacotherapy. The clinical workflow includes administration of a patient‑reported outcome measure — either the PHQ-9 or the youth version PHQ-9M — within a 60‑day window around the 12‑month mark. The billing metric M1020 applies when the adolescent has not achieved remission at twelve months, defined as a PHQ-9/PHQ-9M total score of 5 or greater, or when no PHQ-9/PHQ-9M score was obtained in the required timeframe.
Typical encounter steps:
-
Initial intake and documentation of baseline depression diagnosis and treatment plan.
-
Scheduled 12‑month visit with administration of
PHQ-9orPHQ-9Mwithin +/−60 days of the anniversary of treatment start. -
Scoring and documentation in the medical record. If the score is less than 5, remission is recorded and
M1020does not apply. If score is ≥5 or the measure is missing,M1020applies and is documented with supporting notes on symptom persistence or reason for missing assessment.